Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

EMRs Could Help Discover New Disease Associations

By BiotechDaily International staff writers
Posted on 10 Dec 2013
A new study is repurposing genetic data and electronic medical records (EMRs) to perform a large-scale validation of known disease associations.

Researchers at Vanderbilt University Medical Center (Vanderbilt, Nashville, TN, USA) and other institutions participating in the phenome-wide association study (PheWAS) used genotype data from 13,835 individuals of European descent, exhibiting 1,358 diseases collectively. The team then ran PheWAS on 3,144 single-nucleotide polymorphisms (SNPs), checking each SNP association with each of the 1,358 disease phenotypes. The researchers thus succeeded in identifying 63 previously unknown SNP-disease associations, the strongest of which related to skin diseases.

The researchers also created an online PheWAS catalog that may help understand the influence of many common genetic variants on human conditions. The researchers stressed that PheWAS would be unworkable without the eMERGE Network, of which Vanderbilt is the coordinating center. The network has expanded to nine sites with DNA samples from about 51,000 individuals linked to EMRs. The eMERGE Network is funded by the US National Human Genome Research Institute (Bethesda, MD, USA). The study was published on November 24, 2013, in Nature Biotechnology.

“This study broadly shows that we can take decades of off-the-shelf electronic medical record data, link them to DNA, and quickly validate known associations across hundreds of previous studies; at the same time, we can discover many new associations,” said lead author Josh Denny, MD, MSc, an associate professor of biomedical informatics and medicine. “Our method does not select any particular disease; it searches simultaneously for more than a thousand diseases. By doing this, we were able to show some genes that are associated several diseases or traits, while others are not.”

“If you think about the way genetic research has been done for the last 50 years or more, a lot of it was done through carefully planned clinical trials or observational cohorts,” added Dr. Denny. “This certainly does not supplant those in any way but provides a cost efficient, systematic method to look at many different diseases over time in a way that you really can't do easily with an observational cohort.”

Related Links:

Vanderbilt University Medical Center
eMERGE Network
US National Human Genome Research Institute



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.